莱西康制药

关于 Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and为生物医药企业，从事药品和治疗方案的研发与商业化。 1995年成立。总部位于The Woodlands, TX。

成立时间

1995

首席执行官

Dr. Michael Exton, PhD

员工人数

81

总部地址

The Woodlands, Texas, United States of America

财年结束日

12-31

官方网站

lexpharma.com

公司概况

交易所

US

股票代码

LXRX

市值排名

#3430

市值

676.33M

流通市值

332.86M

总股数

444.96M

流通股数

218.99M

行业与主题板块

浏览全部行业与主题板块